AR003919A1 - POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS IT - Google Patents
POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS ITInfo
- Publication number
- AR003919A1 AR003919A1 ARP960101095A AR10109596A AR003919A1 AR 003919 A1 AR003919 A1 AR 003919A1 AR P960101095 A ARP960101095 A AR P960101095A AR 10109596 A AR10109596 A AR 10109596A AR 003919 A1 AR003919 A1 AR 003919A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- accessory protein
- human
- interleukin
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Esta invención hace disponible por primera vez una proteína accesoria del receptor IL-1 humana que puede ser usado para regular los efectos de IL-1. Elagregado de esta proteina inhibe el efecto de IL-1 en las células.Por lo tanto, un aspecto de lainvención es proveer dicha proteína para el tratamiento decondiciones patológicas causadas por un exceso de actividad de las células que responden a IL-1 mediante el agregado de una cantidad de proteína accesoria delreceptor IL-1R humana (IL-1R AcP)suficiente para inhibir la activación de células por IL-1. Esta metodología también puede ser modificada, y la proteínaaccesoria puede ser usada como agente de rastreo para productos farmacéuticos. La invención comprende además el polinucleótido que codifica a dicha proteína,un vector, una célula huésped, una proteína de fusión que comprende dicha proteína, un anticuerpo que se une específicamente a dicha proteína, unacomposición farmacéutica que la comprende, un procedimiento parala preparación de dicha proteína y el empleo de dicha proteína como sustancia terapéutica parael tratamiento de respuestas inflamatorias o inmunológicas y/o para la regulación y prevención de las actividades inflamatorias o inmunológicas delainterleuquina-1, entre otras afecciones y/o enfermedades.This invention makes available for the first time a human IL-1 receptor accessory protein that can be used to regulate the effects of IL-1. Aggregation of this protein inhibits the effect of IL-1 on cells. Therefore, one aspect of the invention is to provide said protein for the treatment of pathological conditions caused by excess activity of cells that respond to IL-1 by adding of an amount of human IL-1R receptor accessory protein (IL-1R AcP) sufficient to inhibit the activation of cells by IL-1. This methodology can also be modified, and the accessory protein can be used as a tracking agent for pharmaceuticals. The invention further comprises the polynucleotide encoding said protein, a vector, a host cell, a fusion protein comprising said protein, an antibody that specifically binds to said protein, a pharmaceutical composition comprising it, a process for the preparation of said protein and the use of said protein as a therapeutic substance for the treatment of inflammatory or immunological responses and / or for the regulation and prevention of inflammatory or immunological activities of interleukin-1, among other conditions and / or diseases.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37626895A | 1995-01-23 | 1995-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003919A1 true AR003919A1 (en) | 1998-09-30 |
Family
ID=23484321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960101095A AR003919A1 (en) | 1995-01-23 | 1996-01-19 | POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS IT |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0808365A1 (en) |
| JP (1) | JPH10512453A (en) |
| AR (1) | AR003919A1 (en) |
| AU (1) | AU4537096A (en) |
| BR (1) | BR9606837A (en) |
| CA (1) | CA2210724A1 (en) |
| CO (1) | CO4480033A1 (en) |
| CZ (1) | CZ208197A3 (en) |
| EA (1) | EA199700265A1 (en) |
| FI (1) | FI973089A (en) |
| HU (1) | HUP9702458A2 (en) |
| IL (1) | IL116796A0 (en) |
| MX (1) | MX9705501A (en) |
| NO (1) | NO973404D0 (en) |
| PE (1) | PE64396A1 (en) |
| PL (1) | PL321538A1 (en) |
| TR (1) | TR199700652T1 (en) |
| WO (1) | WO1996023067A1 (en) |
| ZA (1) | ZA96333B (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| AU7011696A (en) * | 1996-08-26 | 1998-03-19 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| WO1998024477A1 (en) | 1996-12-06 | 1998-06-11 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| WO1998049309A1 (en) * | 1997-04-30 | 1998-11-05 | F. Hoffmann-La Roche Ag | Rat st38.2 chemokine |
| US6280955B1 (en) * | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| AU755391B2 (en) | 1997-12-23 | 2002-12-12 | Immunex Corporation | SIGIRR DNA and polypeptides |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| US7049095B2 (en) | 2000-10-31 | 2006-05-23 | Immunex Corporation | DNA encoding IL-1 receptor accessory protein |
| GB2375604A (en) * | 2001-05-18 | 2002-11-20 | Warner Lambert Co | Methods for screening using interleukin soluble trimolecular complex |
| SG10201603108QA (en) | 2001-06-26 | 2016-05-30 | Amgen Inc | Antibodies To OPGL |
| KR100453877B1 (en) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR |
| MXPA04001187A (en) * | 2001-08-07 | 2004-07-08 | Immunex Corp | Interleukin-1 receptors in the treatment of diseases. |
| CN101628939B (en) | 2002-09-06 | 2014-06-25 | 安姆根有限公司 | Therapeutic human anti-il-1r1 monoclonal antibody |
| US10765747B2 (en) | 2004-04-02 | 2020-09-08 | Swedish Orphan Biovitrum Ab (Publ) | Methods of reducing aggregation of IL-1ra |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| PL1751175T3 (en) * | 2004-05-05 | 2013-03-29 | Valorisation Recherche Soc En Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP2366786A3 (en) * | 2005-05-05 | 2012-08-29 | VALORISATION HSJ, Société en Commandite | Cytokine receptor modulators and uses thereof |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| US20110044894A1 (en) | 2008-03-26 | 2011-02-24 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| CA2824719C (en) | 2011-01-19 | 2020-06-02 | Cantargia Ab | Anti-il1rap antibodies and their use for treating solid tumours |
| BR112013020220B1 (en) | 2011-02-09 | 2020-03-17 | Natera, Inc. | METHOD FOR DETERMINING THE PLOIDIA STATUS OF A CHROMOSOME IN A PREGNANT FETUS |
| CA2837651A1 (en) * | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
| CN108026172B (en) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | Monoclonal anti-IL-1 RACP antibodies |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| JP2020524519A (en) | 2017-06-20 | 2020-08-20 | ザ メディカル カレッジ オブ ウィスコンシン，インコーポレイテッドＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． | Assessment of transplant complication risk by all cell-free DNA |
| WO2019118926A1 (en) | 2017-12-14 | 2019-06-20 | Tai Diagnostics, Inc. | Assessing graft suitability for transplantation |
| WO2019200228A1 (en) | 2018-04-14 | 2019-10-17 | Natera, Inc. | Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna |
| TW202021618A (en) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | Anti-il1rap antibodies and methods of use thereof |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| WO2021236962A1 (en) | 2020-05-20 | 2021-11-25 | The Medical College Of Wisconsin, Inc. | Compositions and methods for inhibiting cytokine-release syndrome |
| WO2022247937A1 (en) * | 2021-05-28 | 2022-12-01 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric il1rap |
| WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
-
1996
- 1996-01-15 PE PE1996000031A patent/PE64396A1/en not_active Application Discontinuation
- 1996-01-16 ZA ZA96333A patent/ZA96333B/en unknown
- 1996-01-17 HU HU9702458A patent/HUP9702458A2/en unknown
- 1996-01-17 IL IL11679696A patent/IL116796A0/en unknown
- 1996-01-17 JP JP8522598A patent/JPH10512453A/en active Pending
- 1996-01-17 CZ CZ972081A patent/CZ208197A3/en unknown
- 1996-01-17 EA EA199700265A patent/EA199700265A1/en unknown
- 1996-01-17 WO PCT/EP1996/000181 patent/WO1996023067A1/en not_active Application Discontinuation
- 1996-01-17 MX MX9705501A patent/MX9705501A/en unknown
- 1996-01-17 EP EP96901291A patent/EP0808365A1/en not_active Withdrawn
- 1996-01-17 AU AU45370/96A patent/AU4537096A/en not_active Abandoned
- 1996-01-17 TR TR97/00652T patent/TR199700652T1/en unknown
- 1996-01-17 CA CA002210724A patent/CA2210724A1/en not_active Abandoned
- 1996-01-17 PL PL96321538A patent/PL321538A1/en unknown
- 1996-01-17 BR BR9606837A patent/BR9606837A/en unknown
- 1996-01-19 AR ARP960101095A patent/AR003919A1/en unknown
- 1996-01-22 CO CO96002329A patent/CO4480033A1/en unknown
-
1997
- 1997-07-22 FI FI973089A patent/FI973089A/en unknown
- 1997-07-23 NO NO973404A patent/NO973404D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996023067A1 (en) | 1996-08-01 |
| CZ208197A3 (en) | 1997-11-12 |
| EP0808365A1 (en) | 1997-11-26 |
| BR9606837A (en) | 1998-05-26 |
| PE64396A1 (en) | 1997-01-28 |
| EA199700265A1 (en) | 1998-04-30 |
| FI973089A0 (en) | 1997-07-22 |
| ZA96333B (en) | 1996-07-23 |
| MX9705501A (en) | 1997-10-31 |
| JPH10512453A (en) | 1998-12-02 |
| TR199700652T1 (en) | 1998-02-21 |
| HUP9702458A2 (en) | 1998-04-28 |
| AU4537096A (en) | 1996-08-14 |
| IL116796A0 (en) | 1996-05-14 |
| NO973404L (en) | 1997-07-23 |
| PL321538A1 (en) | 1997-12-08 |
| CA2210724A1 (en) | 1996-08-01 |
| NO973404D0 (en) | 1997-07-23 |
| FI973089A (en) | 1997-07-22 |
| CO4480033A1 (en) | 1997-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003919A1 (en) | POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS IT | |
| Vitaliano et al. | The relative importance of risk factors in nonmelanoma carcinoma | |
| Rosenthal et al. | Seasonal affective disorders | |
| AR010348A1 (en) | CETOBENZAMIDES, THEIR USE AND PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM | |
| BR0213846A (en) | methods of selectively inducing apoptosis in dr5-expressing target cells, inhibiting proliferation of dr5-expressing target cells, and treating a patient having an inflammatory disease or autoimmune disease; | |
| SV2003001148A (en) | DERIVATIVES OF BENZAMIDA TIAZOL AND PHARMACEUTICAL COMPOSTIONS TO INHIBIT THE PROLIFERATION OF CELLS, AND METHODS FOR ITS USE REF. NO.0097-01-SV | |
| CY1109868T1 (en) | CD81 PROFESSIONAL SUBSCRIPTION PROTECTOR C | |
| Fagan | Remembering the lessons of basic pharmacology | |
| DK1401422T3 (en) | Halogen-containing composition, process for its preparation and uses thereof | |
| Abelaira et al. | Ketamine exhibits different neuroanatomical profile after mammalian target of rapamycin inhibition in the prefrontal cortex: the role of inflammation and oxidative stress | |
| Kim et al. | Different patterns of emotional eating and visuospatial deficits whereas shared risk factors related with social support between anorexia nervosa and bulimia nervosa | |
| Bastos Moura et al. | A novel model of megavoltage radiation-induced oral mucositis in hamsters: Role of inflammatory cytokines and nitric oxide | |
| Muders et al. | Effects of Traumeel (Tr14) on Exercise‐Induced Muscle Damage Response in Healthy Subjects: A Double‐Blind RCT | |
| ES2166770T3 (en) | MONOCLONAL ANTIBODIES AGAINST GANGLIOSIDS AND THEIR USES IN THE SPECIFIC ACTIVE IMMUNOTHERAPY OF MALIGNOUS TUMORS. | |
| O’Connor et al. | Endurance exercise attenuates juvenile irradiation-induced skeletal muscle functional decline and mitochondrial stress | |
| ES2144054T3 (en) | TRI COMPLEXES (PLATINUM). | |
| ES2061521T3 (en) | PROTEINS WITH GLUTATION-S-TRANSFERASE ACTIVITY, DNA SEQUENCES, ANTIBODIES, POXVIRUSES AND MEDICINES FOR THE PREVENTION OF EQUISTOSOMIASIS. | |
| Dogra et al. | Phototherapy and photochemotherapy in childhood dermatoses | |
| Orjuela‐Grimm et al. | Sunlight exposure in infancy decreases risk of sporadic retinoblastoma, extent of intraocular disease | |
| Ghoreishi | Heat shock proteins in the pathogenesis of inflammatory skin diseases | |
| ES2110057T3 (en) | MEDICINAL COMPOSITION CONTAINING TCF-II. | |
| EA199901061A1 (en) | NEW SALTS OF HRV-PEPTIDES WITH ORGANOPROTECTIVE ACTIVITY, METHOD OF THEIR RECOVERY AND THEIR USE IN THERAPY | |
| Goldstein et al. | Combined use of benserazide and carbidopa in Parkinson's disease | |
| Baliño et al. | Role of CA2+/calmodulin on ethanol neurobehavioral effects | |
| BR112022027124A2 (en) | FORMULATIONS TO PROMOTE HYDRATION AND METHODS OF THEIR USE |